ConexiantFDA Drops Warning From GLP-1 RAs

FDA requested removal of suicidal ideation warnings from Saxenda, Wegovy, and Zepbound after analyzing 107,910 patients across 91 trials showing no psychiatric risk signal. This reverses 2023 safety concerns triggered by postmarketing reports and aligns weight loss formulations with diabetes medications that never carried these warnings.

🎯 PROFESSIONAL IMPACT

• FDA meta-analysis found no increased risk of suicidal ideation, self-harm, anxiety, depression, or psychosis compared to placebo in comprehensive pooled trial data.
• Sentinel System study of 2.2 million GLP-1 RA users showed no elevated intentional self-harm risk versus SGLT2 inhibitor users after adjusting for baseline mental health factors.
• Weight management formulations now align with diabetes medications in safety labeling, removing regulatory inconsistency that created patient counseling confusion across indications.
• Original warnings were based on older weight loss drug risks, not GLP-1 RA-specific evidence, representing precautionary labeling that postmarketing surveillance failed to validate.

💡 PRACTICE APPLICATIONS

• Counsel patients that previous suicide warnings are being removed based on comprehensive safety data review.
• Continue GLP-1 RA therapy without psychiatric screening beyond standard obesity/diabetes care protocols.
• Refer patients reporting mood changes for mental health evaluation regardless of GLP-1 RA status.
• Document updated FDA safety conclusions when discussing treatment risks during contraception counseling for reproductive-age patients.

More on GLP-1s